www.nature.com/eye

CORRIGENDUM

Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study

FG Holz, R Tadayoni, S Beatty, AR Berger, MG Cereda, P Hykin, G Staurenghi, K Wittrup-Jensen, J Nilsson, K Kim and S Sivaprasad

Eye (2017) 31, 166; doi:10.1038/eye.2016.276

Correction to: *Eye* (2016) **30**, 1063–1071; doi:10.1038/eye.2016.90; published online 20 May 2016

Since the publication of this article, the authors would like to correct a mistake in the heading of Table 2. The lower 95% confidence interval (CI) and upper 95% CI should be replaced with the

Year 2 coefficient and *P*-value, respectively. Accordingly, the first column should be replaced with Year 1 coefficient and *P*-value (as shown). The coefficients for Year 1 are quoted in the text, but this does not change the interpretation of the findings.

The authors would like to apologise for this error.

 Table 2
 Correlation between number of ranibizumab injections and candidate variables (all countries; over 2 years)

| Parameters | Year 1 | | Year 2 | |
|---|--------------------------|---------|--------------------------|---------|
| | Coefficient ^a | P-value | Coefficient ^a | P-value |
| Age at start of therapy | -0.0289 | 0.1141 | -0.0378 | 0.056 |
| Sex | 0.0171 | 0.384 | -0.0126 | 0.5193 |
| Health insurance (public) | -0.028 | 0.1544 | -0.053 | 0.0071 |
| Reimbursement type (national standards) | 0.1297 | < 0.001 | 0.1524 | < 0.001 |
| Medical history (prior disease) | -0.0268 | 0.1711 | -0.0354 | 0.0703 |
| Medical history (concomitant disease) | -0.0003 | 0.9866 | 0.018 | 0.3595 |
| Medical history (ocular disease) | -0.0246 | 0.2083 | -0.0331 | 0.0905 |
| Baseline VAS | -0.0088 | 0.6758 | 0.0424 | 0.0444 |
| Treatment duration | 0.5645 | < 0.001 | 0.7389 | < 0.001 |
| Switch to other treatments | 0.0275 | 0.1599 | 0.0632 | 0.0012 |
| Baseline presence of retinal breaks ^b | NA | NA | NA | NA |
| Baseline presence of pigment epithelial detachment | 0.0821 | 0.0038 | 0.1163 | < 0.001 |
| Number of ophthalmoscopies | 0.2499 | < 0.001 | 0.3425 | < 0.001 |
| Optical coherence tomography, <i>n</i> | 0.3777 | < 0.001 | 0.4955 | < 0.001 |
| Fluorescein angiography, <i>n</i> | 0.0509 | 0.0093 | 0.1154 | < 0.001 |
| ICGA, n | -0.0341 | 0.0814 | 0.0302 | 0.1228 |
| Ophthalmoscopies/optical coherence tomography, <i>n</i> | 0.3608 | < 0.001 | 0.4673 | < 0.001 |
| Number of monitoring visits | -0.1349 | < 0.001 | 0.0239 | 0.2224 |

Abbreviations: ICGA, indocyanine green angiography; NA, not available; VAS, visual acuity score. ^aPearson's correlation coefficient at 0.05 significance level. ^bNo observation with retinal break episode. The bold values highlights the candidate instrumental variables.